Results 171 to 180 of about 204,699 (375)

Familial Interstitial Pulmonary Fibrosis: A Large Family with Atypical Clinical Features

Canadian Respiratory Journal, 2010
A large kindred of familial pulmonary fibrosis is reported. Six members from the first two generations of this particular kindred were described more than 40 years previously; six more individuals from the third and fourth generations have also been ...
Ranji Chibbar, John A Gjevre, Francis Shih, Heather Neufeld, Edmond G Lemire, Derek A Fladeland, Donald W Cockcroft   +6 more
doaj   +1 more source

Viruses and idiopathic pulmonary fibrosis [PDF]

, 1997
JJ Egan, Ashley Woodcock, James P. Stewart   +2 more
openalex   +1 more source

Modeling Progressive Fibrosis with Pluripotent Stem Cells Identifies an Anti-fibrotic Small Molecule. [PDF]

, 2019
Progressive organ fibrosis accounts for one-third of all deaths worldwide, yet preclinical models that mimic the complex, progressive nature of the disease are lacking, and hence, there are no curative therapies. Progressive fibrosis across organs shares
Ahadome, Sarah D, Aros, Cody J, Bhatt, Kush V, Chung, Katherine, Clark, Amander T, Damoiseaux, Robert, Darmawan, Kelly F, Durra, Abdo, Gomperts, Brigitte N, Graeber, Thomas G, Karumbayaram, Saravanan, Manze, Chase C, Mehrabi, Mehrsa, Minasyan, Aspram, Paul, Manash K, Rickabaugh, Tammy M, Sandlin, Jenna M, Shia, David W, Vijayaraj, Preethi, Wallace, W Dean, Wilkinson, Dan C, Yan, Weihong   +21 more
core   +1 more source

Global Disproportionality Analysis of Adverse Event Reports on Interstitial Lung Diseases for Cancer‐Targeted Therapies, 1968–2024

Respirology, EarlyView.
ABSTRACT Background and Objectives The increasing complexity of interstitial lung disease (ILD) related to cancer‐targeted monoclonal antibodies (mAbs) has emerged as a significant clinical concern. Thus, this study aimed to investigate reporting signals of four ILD subtypes detected with cancer‐targeted mAbs.
Jinyoung Jeong, Hyunjee Kim, Sooji Lee, Jiyoung Hwang, Lee Smith, Ho Geol Woo, Jaehyeong Cho, Dong Keon Yon   +7 more
wiley   +1 more source

Idiopathic nonspecific interstitial pneumonia/fibrosis: comparison with idiopathic pulmonary fibrosis and BOOP [PDF]

, 1998
Shuntaro Nagai, Masanori Kitaichi, Harumi Itoh, Koichi Nishimura, Takashi Izumi, TV Colby   +5 more
openalex   +1 more source

Telomerase and idiopathic pulmonary fibrosis

Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, 2012
Idiopathic pulmonary fibrosis (IPF) is the most common manifestation of telomere-mediated disorders. Germline mutations in the essential telomerase genes, hTERT and hTR, are the causal genetic defect in up to one-sixth of pulmonary fibrosis families. The presence of telomerase mutations in this subset is significant for clinical decisions as affected ...
openaire   +3 more sources

Rapid Serological Detection of Anti‐GM‐CSF Autoantibodies in Autoimmune Pulmonary Alveolar Proteinosis Using a Novel Immunochromatographic Test

Respirology, EarlyView.
We developed a novel ICT with high clinical performance that can distinguish APAP patients from those with other pulmonary diseases. The rapid and simple detection of GMAbs in serum provided a new practical method for the diagnosis of APAP. ABSTRACT Background and Objectives Anti‐GM‐CSF autoantibodies (GMAbs) are essential biomarkers for diagnosing ...
Chika Narita, Kenjiro Shima, Jun‐ichiro Sekiguchi, Yasuyuki Ozeki, Makoto Akiwa, Shohei Koike, Sachiko Yuki, Keiichi Akasaka, Toshiaki Kikuchi, Nobutaka Kitamura, Koh Nakata   +10 more
wiley   +1 more source

Dyskeratosis Congenita Associated Non-Specific Interstitial Pneumonia [PDF]

Journal of Krishna Institute of Medical Sciences University, 2017
Dyskeratosis Congenita (DC) is a rare inherited disorder of ectodermal dysplasia. It consists of a classical mucocutaneous triad of abnormal skin pigmentation, nail dystrophy and leukoplakia. Pulmonary disease is seen in 10-15%.
Unnati D. Desai , Jyotsna M. Joshi
doaj  

Atomic Force Microscopy‐Based Nanomechanical Signatures for Staging Classification and Drug Response in Pulmonary Fibrosis

Small, EarlyView.
Atomic Force Microscopy (AFM) reveals nanomechanical fingerprints (NMFs) that track the progression of pulmonary fibrosis (PF) and response to therapy. These NMFs correlate with collagen I content and gene expression, offering a novel biomarker for disease staging and treatment monitoring.
Andreas Stylianou, Katerina Polemidiotou, Vassilis Alimisis, Fotios Mpekris, Chrysovalantis Voutouri, Meropi Mari, George Filippidis, Andreas Zachariades, Stylianos‐Vasileios Kontomaris, Paul P Sotiriadis, Vasiliki Gkretsi, Triantafyllos Stylianopoulos   +11 more
wiley   +1 more source

DLD‐HLNP/P@IR780 for efficient lung‐parenchyma accumulation to treat idiopathic pulmonary fibrosis

VIEW, EarlyView.
DLD‐HLNP/P@IR780 was synthesized to target to lung and treat IPF by releasing pirfenidone. It could effectively traverse pulmonary ECB and accumulate in lung parenchyma by IR780 binding to CD300LF and MRC1 which are abundantly and specifically expressed on pulmonary endothelial cell and pulmonary macrophages.
Mengzhu Wang, Na Zhuang, Juan Feng, Cheng Qian   +3 more
wiley   +1 more source